Alzheimer's Biomarkers Consortium — Down Syndrome (ABC-DS)
Exploring the Connection Between Down Syndrome and Alzheimer's Disease
More information about the newly funded next iteration of ABC-DS (U19AG068054) will be available soon.
The ABC-DS study is a joint study conducted by two groups of research collaborators—Neurodegeneration in Aging Down Syndrome (NiAD) and Alzheimer's Disease in Down Syndrome (ADDS)—and is currently funded at $46 million by the National Institute on Aging (NIA) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), both part of NIH.
- Goals and Measures
- Study Sites and Investigators
- Information for Participants and Families
- Available Data
Adults with Down syndrome (DS) are at high risk for early onset of Alzheimer's disease (AD). Virtually all adults with DS have neuropathological changes consistent with AD by age 40, including deposition of Aβ in diffuse and neuritic plaques, and most will develop clinical dementia by their late 60s. The high risk for AD has been attributed, at least in part, to triplication and overexpression of the gene for amyloid precursor protein (APP) on chromosome 21, leading to elevated levels of Aβ peptides. However, there is wide variation in age at onset of dementia, ranging from under 40 to over 70 years of age. This range in age at onset suggests that additional genetic, biological, and environmental factors modify the rate and degree of Aβ deposition or clearance, and may be important modifiers of risk that accelerate or slow disease progression.
Early diagnosis is critically important given that effective prevention and treatment must precede irreversible neuronal loss. However, early AD-related changes are especially difficult to identify in adults with DS because of variable levels of lifelong cognitive impairments. Thus, development of empirically supported methods for early diagnosis of dementia in DS, biological characterization of the preclinical and early phases of AD, and identification of risk factors for AD progression are critical to the early diagnosis of dementia and for the development of effective intervention and treatment.
Goals and Measures
The overall goals of this study are to:
- Identify sensitive neuropsychological measures of cognitive decline, imaging, blood-based, and genetic biomarkers associated with transition from normal aging to mild cognitive impairment to clinical dementia in adults with DS
- Identify critical factors that link cerebral Aβ deposition to neurodegeneration and, ultimately, dementia
- Understand the relationships between biomarkers and pathways implicated in AD pathogenesis
- Provide rapid public access to all data, without embargo, and access to the biological samples by qualified scientific investigators
Common core measures, collected at multiple time points to support longitudinal analyses, include:
- Direct cognitive and functional measures (tests of memory, visual spatial construction, language, executive processing and speed, mental status, and gait)
- Caregiver questionnaires (queries on functional abilities, mental status, neuropsychiatric symptoms, and dementia screening)
- Medical and neurological assessments (personal and family health history, medication usage, and a brief physical and neurological examination)
- Neuroimaging biomarkers (MRI-based measures of cortical thickness and volume, white matter abnormalities and connectivity, as well as amyloid-, tau-, and FDG-PET)
- Blood-based biomarkers (a proteomics panel with proinflammatory markers, a metabolomics panel, and an assay of plasma Aβ peptides—Aβ40, Aβ42, Aβ40/Aβ42 ratio, tau, and neurofilament light change protein)
- Genetic studies (genome-wide association analysis focusing on variants in genes associated with AD, age at onset of AD and memory decline, and with individual differences in blood-based, imaging, and CSF biomarkers that are found to be associated with clinical disease progression including Aβ42, P181-tau, and total tau)
There will be 3-4 cycles of assessment, at approximately 16-month intervals, over the 5-year study. However, some procedures will only be included in selected cycles.
The NiAD sites will recruit 180 adults with DS (10% with dementia) and 40 sibling controls, age 25 years and older. The ADDS sites will recruit 200-225 adults with DS (25% with dementia), age 40 years and older.
Study Sites and Investigators
|Site||Investigator & Study Coordinator|
University of Pittsburgh (Coordinating Center), Pittsburgh, PA
|Ben Handen, Ph.D., Co-PI
William Klunk, M.D., Ph.D., Co-PI
Cathy Wolfe, Study Coordinator
University of Wisconsin Madison, WI
|Brad Christian, Ph.D., Co-PI
Renee Makuch, Study Coordinator
University of Cambridge, Cambridge, UK
|Shahid Zaman, M.D., Ph.D., Site PI
Monika Grigorova, Study Coordinator
|Washington University in St. Louis, St. Louis, MO||Beau Ances, M.D., Ph.D. Site PI
Elizabeth Westerhaus, Study Coordinator
|Site||Investigator & Study Coordinator|
Columbia University (Coordinating Center), New York, NY
|Nicole Schupf, Ph.D., Co-PI
Deborah Pang, Study Coordinator
Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
|Mei-Cheng Wang, Ph.D., Site PI|
University of California, Irvine, Irvine, CA
|Ira Lott, M.D., Co-PI
Wayne Silverman, Ph.D., Co-PI
Eric Doran, Study Manager
Alicia Hernandez, Study Coordinator
Harvard/Massachusetts General Hospital, Boston, MA
|Florence Lai, M.D., Site PI
Diana Rosas, M.D., Site PI
Courtney Jordan, Study Coordinator
Hackensack University Medical Center, Nutley, NJ
|Benjamin Tycko, M.D., Ph.D., Site PI|
The New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY
|Sharon Krinsky-McHale, Ph.D., Site PI
Deborah Pang, Study Coordinator
University of North Texas Health Science Center, Fort Worth, TX
|Sid O'Bryant, Ph.D., Site PI|
(Note that enrollment is limited to sites with study coordinators listed)
ABC-DS is committed to making clinical, cognitive and biomarker (fluid and imaging) data and biospecimen samples available to researchers interested in Down syndrome and neurodegenerative disease. ABC-DS data are transferred to the University of Southern California Laboratory of Neuro Imaging (LONI), for harmonization, documentation and de-identification; and biospecimen samples are transferred and managed by the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) and an ABC-DS biospecimen bank.
As data and biospecimens are available, qualified investigators can submit requests for access to data and samples; and all requests will be reviewed by ABC-DS investigators and NIH staff. Approved data requests will be sent to LONI, and researchers will have access to the clinical, cognitive and neuroimaging data listed below. Upon approval and availability of biospecimen samples, NCRAD will distribute DNA, plasma and serum, and the ABC-DS biospecimen bank will distribute the CSF; the associated data will be managed by LONI.
Data and biospecimens available for requests:
- Plasma in 0.25 mL (250 uL) aliquots
- Serum in 0.25 mL (250 uL) aliquots
- Buffy coat in 1 mL aliquots
- CSF in 15-20 mL aliquots
- Medical and psychiatric history
- Physical and neurological exam results
- Caregiver assessment tools on adaptive functioning (Vineland 3), AD symptoms (DLD and NTG-EDSD), and psychiatric symptoms (Reiss)
- Neuropsychological battery results (DSMSE, Block Design, Tinetti Gait, Modified Cats & Dogs Task, Cued Recall, Purdue Pegboard, Rivermead)
- Consensus diagnosis
The neuroimaging data are selected to mirror the ADNI protocols
- PET – amyloid, tau, and FDG
- MRI – T1-weighted structural, T2 FSE, T2-FLAIR, T2*, ASL, DTI and rs-fMRI.
- APOE genotype
- GWAS (~760K SNPs)
- Data on over 40 sibling controls of participants with Down syndrome
- Primarily biospecimens and neuroimaging data
- Complete and submit the data/sample request form (ABC-DS Data or Biospecimen Request Form)
- Review and sign the ABC-DS Data Use Agreement
Note: Details and information for the collected data and biospecimens can be found in the ABC-DS Data Dictionary (PDF, 580K).
Any questions about ABC-DS data and/or biospecimens should be directed to: Joni Vander Bilt (Email Joni Vander Bilt).
Publication and Ancillary Studies Committee Co-Chairs
Brad Christian (Email Brad Christian)
Mark Mapstone (Email Mark Mapstone)
Sid O’Bryant (Email Sid O'Bryant)